Prostate Clinic London

What Is Abiraterone for Prostate Cancer and How Does It Work?

If you have advanced prostate cancer or selected high-risk non-metastatic disease, your doctor may recommend abiraterone to slow cancer growth and improve treatment outcomes. It works by blocking an enzyme called CYP17, reducing the hormones that help prostate cancer cells grow.

You’ll usually take abiraterone alongside androgen deprivation therapy (ADT) and a prescribed dose of prednisolone or prednisone, which helps reduce certain hormonal side effects. Your specialist will monitor your blood pressure, potassium and liver function for side effects, while also checking your PSA, symptoms and scans when needed to assess how well the treatment is working.

What Exactly Is Abiraterone?

Abiraterone is usually supplied as abiraterone acetate, which your body converts into the active medicine. It blocks an enzyme called CYP17, reducing the hormones that can help your prostate cancer grow.

Your specialist may recommend it alongside androgen deprivation therapy (ADT) to improve cancer control, even when your cancer still responds to hormone treatment. It’s used for certain types of advanced prostate cancer and selected high-risk non-metastatic cases, depending on your diagnosis and treatment plan.

How Does Abiraterone Block Testosterone and Other Androgens?

Your body produces hormones called androgens, including testosterone, which can help prostate cancer grow. Abiraterone blocks an enzyme called CYP17, which your body needs to make these hormones. This helps reduce androgen synthesis in your testes, adrenal glands and prostate tumour tissue. You’ll usually continue medical ADT to suppress testicular testosterone production unless you’ve already had surgical castration.

Standard hormone therapy mainly lowers the testosterone made by your testes. Abiraterone goes a step further by reducing hormone production from other sources too. This means your treatment can suppress androgen production more extensively than ADT alone, although it cannot completely eliminate every androgen or guarantee that your cancer will stop growing.

Why Do You Still Need ADT If Abiraterone Lowers Androgens?

You’ll usually continue ADT, often given as hormone injections, while taking abiraterone because the treatments work in different ways. ADT mainly reduces testosterone produced by your testes, while abiraterone lowers androgen production from other sources, including your adrenal glands and prostate tumour tissue.

Using both treatments gives you a stronger reduction in the hormones that can help your cancer grow. Your specialist will recommend this combination if it’s suitable for your type and stage of prostate cancer.

How ADT, Abiraterone and Prednisolone Work Together

TreatmentMain purpose
ADTSuppresses testicular testosterone production
AbirateroneBlocks CYP17A1 and reduces androgen synthesis from additional sources
Prednisone/prednisoloneReduces ACTH-driven mineralocorticoid side effects caused by CYP17 inhibition
Radiotherapy, when indicatedTreats cancer in the prostate/pelvis rather than acting as hormone therapy

Why Is Prednisone or Prednisolone Given With Abiraterone?

You’ll usually take a prescribed dose of prednisone or prednisolone with abiraterone to reduce the risk of certain hormonal side effects. Abiraterone changes how your body produces hormones, which can lead to high blood pressure, low potassium and fluid retention. The steroid helps control the hormonal changes that cause these problems.

It’s important to take your steroid exactly as prescribed and never stop it suddenly without speaking to your doctor. If you become seriously unwell, develop an infection or need surgery, your specialist may need to adjust your steroid treatment to prevent adrenal insufficiency.

Clinical Note

Prednisone or prednisolone is not given simply as a general anti-inflammatory medicine. It helps counter the hormonal changes caused by CYP17 inhibition and reduces mineralocorticoid-related problems such as hypertension, low potassium and fluid retention.

Do not stop or alter the steroid dose without advice from your cancer team. If you become acutely unwell, develop a serious infection or need surgery, your corticosteroid requirements may need reassessment because adrenal insufficiency can occur if steroid cover becomes inadequate.

When Is Abiraterone Used in Metastatic Hormone-Sensitive Prostate Cancer?

If your prostate cancer has spread but is still responding to hormone therapy, your doctor may recommend adding abiraterone and prednisone to ADT. This helps reduce the hormones that can encourage your cancer to grow.

Research has shown that this combination can help you live longer and delay cancer progression compared with ADT alone. NICE also recommends it as an option for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. Your specialist will consider your health, cancer stage and previous treatment before deciding whether it’s suitable for you.

Can Abiraterone Be Used Before the Cancer Becomes Metastatic?

Yes. If you have selected high-risk prostate cancer that hasn’t spread, your specialist may recommend abiraterone alongside ADT, with radiotherapy where appropriate. The STAMPEDE trial found that adding abiraterone and prednisolone improved survival and delayed the development of metastases.

In England, eligible patients can receive this treatment through the NHS following specialist assessment. For eligible high-risk non-metastatic disease, you’ll usually take abiraterone for up to two years, unless your cancer progresses or significant side effects require treatment to stop.

UK Guidance Note

NHS England introduced routine commissioning of abiraterone acetate plus prednisolone for eligible high-risk hormone-sensitive non-metastatic prostate cancer from January 2026. This includes selected newly diagnosed high-risk disease and relapsing disease with specified high-risk features.

NHS England’s January 2026 commissioning policy describes this use as off-label, although licensing information can vary between abiraterone products. Your specialist will check the relevant product licence and NHS eligibility criteria before recommending treatment following multidisciplinary assessment.

How Does Abiraterone Fit With Radiotherapy in High-Risk Localised Disease?

If you have high-risk localised prostate cancer, your specialist may recommend abiraterone alongside radiotherapy and long-term ADT. Abiraterone doesn’t replace radiotherapy; it adds to your treatment by reducing the hormones that can help cancer cells grow.

You won’t necessarily need this combination, as it’s only suitable for selected patients. Your specialist will look at your cancer risk, overall health and the possible side effects before deciding whether adding abiraterone is right for you.

Evidence Note

The key evidence for adding abiraterone in high-risk non-metastatic hormone-sensitive prostate cancer comes from the STAMPEDE platform. Eligible patients had node-positive disease or other specified high-risk features, and most patients for whom radiotherapy was appropriate received local radiotherapy alongside long-term ADT.

Adding abiraterone-based therapy improved both metastasis-free survival and overall survival compared with ADT alone. NHS England summarises six-year overall survival as approximately 86% with abiraterone-based treatment versus 77% with standard treatment.

What Is Metastatic Castration-Resistant Prostate Cancer?

If your prostate cancer continues to grow despite ADT keeping your testosterone levels very low, it may be called castration-resistant prostate cancer. This doesn’t mean hormones no longer matter. Your cancer cells may still use tiny amounts of androgens to grow, even when testosterone is suppressed.

Abiraterone can help by reducing androgen production further. If your cancer has also spread, your specialist may recommend it alongside ongoing ADT, depending on your previous treatments and overall health.

How Effective Is Abiraterone in Castration-Resistant Prostate Cancer?

If your prostate cancer has spread and continues to grow despite hormone therapy, abiraterone may help you live longer and slow the cancer’s progression. Clinical trials have shown benefits both before and after chemotherapy, particularly when abiraterone is taken with prednisone.

Your specialist will look at which treatments you’ve already had and how your cancer has responded before deciding whether abiraterone is suitable for you. This helps ensure your next treatment fits your individual needs.

Research Insight

Abiraterone demonstrated a survival benefit in two pivotal phase 3 trials of metastatic castration-resistant prostate cancer: one after docetaxel chemotherapy and another before chemotherapy. In the updated COU-AA-301 analysis, involving men with metastatic castration-resistant prostate cancer that had progressed after docetaxel, median overall survival was 15.8 months with abiraterone plus prednisone versus 11.2 months with placebo plus prednisone.

In COU-AA-302, involving men with metastatic castration-resistant prostate cancer who had not received chemotherapy, median overall survival was 34.7 months with abiraterone plus prednisone versus 30.3 months with placebo plus prednisone.

Does Abiraterone Work Forever?

Abiraterone can keep your prostate cancer under control for months or even years, but it usually doesn’t work forever. Over time, your cancer may become resistant, causing your PSA levels to rise, new changes to appear on scans or symptoms to develop.

If this happens, it doesn’t mean your treatment was unsuccessful. Your specialist will review your results and discuss the next steps, which may include chemotherapy, targeted treatments or other options based on your cancer and previous treatment.

How Do You Take Abiraterone?

You’ll usually take abiraterone once daily at a dose of 1,000 mg, commonly as two 500 mg tablets or four 250 mg tablets, depending on your prescribed product. For standard tablets, take your dose at least two hours after food and avoid eating for at least one hour afterwards. Follow the instructions supplied with your specific medicine, and ask your pharmacist or cancer team if you’re unsure.

You’ll also take prescribed prednisone or prednisolone alongside ongoing ADT, unless you’ve had surgical castration. Common regimens use 5 mg daily for hormone-sensitive metastatic disease and 10 mg daily for metastatic castration-resistant disease. Your oncologist will confirm the correct dose for you, so never change it yourself. If you miss a dose, follow your medicine’s instructions and do not take an extra dose to make up for it.

What Side Effects Can Abiraterone Cause?

Abiraterone can affect your blood pressure, potassium balance, fluid levels and liver function. Some symptoms may also come from the ADT or corticosteroid taken alongside it, so tell your cancer team about any new or worsening problems.

  • High blood pressure: CYP17 inhibition can increase mineralocorticoid activity, which may raise your blood pressure.
  • Low potassium: Reduced potassium can cause weakness, muscle cramps or, in more severe cases, heart-rhythm problems.
  • Fluid retention: You may notice swollen ankles, leg swelling or unexpected weight gain.
  • Liver changes: Abiraterone can raise liver enzymes even when you feel well, which is why regular blood tests are needed.
  • Tiredness: Fatigue is common during systemic prostate-cancer treatment and may have several contributing causes.
  • Heart-related effects: Fluid retention, hypertension and low potassium can place extra strain on your cardiovascular system, particularly if you already have heart disease.
  • ADT-related effects: Because abiraterone is usually taken with ongoing ADT, you may also experience hot flushes, reduced libido, erectile problems, loss of muscle mass or reduced bone density.
  • Steroid-related effects: Prednisone or prednisolone can cause additional side effects, particularly with longer-term use, so your prescribed dose should not be changed without medical advice.

Contact your cancer team promptly if you develop marked swelling, severe weakness, palpitations, worsening breathlessness or yellowing of your skin or eyes. Seek emergency care for fainting with serious illness, chest pain, severe breathlessness or collapse.

Why Are Potassium and Blood Pressure Monitored?

Abiraterone can change how your body controls salt, water and potassium. This may cause high blood pressure, low potassium, swollen ankles or fluid build-up, which can sometimes put extra strain on your heart.

Your specialist will usually check your blood pressure, potassium and fluid retention at least monthly, with more frequent checks if you’re at significant risk of heart failure. If your results become unsafe or you develop substantial swelling, treatment may need to be paused while the problem is managed.

Why Does Abiraterone Require Liver Blood Tests?

Abiraterone can affect your liver, sometimes causing raised liver enzymes without any noticeable symptoms. This means you may feel perfectly well even when your blood results show a problem.

Your specialist will check your liver function before treatment, every two weeks for the first three months and monthly afterwards. If significant abnormalities occur, treatment may need to be paused, restarted at a reduced dose after recovery or stopped permanently if liver injury is severe.

Is Abiraterone Safe If You Have Heart Problems?

If you already have heart problems, you may still be able to take abiraterone, but your specialist will need to assess the risks carefully. The treatment can raise your blood pressure, lower potassium and cause fluid retention, which may put extra strain on your heart.

Your specialist may work with your GP or cardiologist to monitor your heart health and adjust your medicines if needed. Having heart disease doesn’t automatically rule out abiraterone, but you may need closer monitoring during treatment.

How Do Specialists Decide Whether Abiraterone Is Right for You?

Your specialist will review your prostate cancer stage and previous treatments to decide whether abiraterone is suitable. They’ll also assess your heart and liver health, blood pressure, potassium and other medicines. Tell your specialist if you’re receiving radium-223, because it must not be combined with abiraterone and prednisone or prednisolone due to an increased risk of fractures and other serious complications.

If your doctor recommends abiraterone, ask why it’s suitable for your cancer stage, what benefits you can expect and what alternatives are available. This will help you understand your treatment plan and what to expect next.

Myth vs Fact

MythFact
Abiraterone is chemotherapy.It is an androgen-biosynthesis inhibitor used as hormone-based systemic therapy.
Abiraterone replaces ADT.ADT usually continues unless you have had surgical castration.
Prednisolone is optional.Corticosteroid treatment is an important part of standard abiraterone regimens.
You can take abiraterone with food.Standard tablets must be taken on an empty stomach because food greatly increases drug exposure.
Abiraterone is only for metastatic cancer.NHS England now commissions it for selected high-risk non-metastatic hormone-sensitive disease.
Every abiraterone product has identical licensing.NHS commissioning eligibility and product licensing may differ.
Abiraterone works permanently.Cancer can eventually develop resistance.
A normal PSA alone proves treatment is working.Specialists also assess symptoms, imaging and other clinical findings.

Key Takeaways

  • Abiraterone acetate is converted into active abiraterone in the body.
  • It inhibits CYP17A1, reducing androgen production.
  • It is generally used with ongoing ADT, not instead of ADT.
  • Prednisone or prednisolone helps control mineralocorticoid side effects.
  • Hormone-sensitive and castration-resistant disease may use different corticosteroid doses.
  • Abiraterone is established in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
  • Since January 2026, NHS England also commissions it for selected high-risk hormone-sensitive non-metastatic disease.

Frequently Asked Questions

1. What is abiraterone used for in prostate cancer?
Abiraterone is a hormone-based treatment used for certain types of advanced prostate cancer and selected high-risk non-metastatic cases. It reduces the hormones that help cancer cells grow and is usually given alongside ADT and prednisolone or prednisone.

2. How does abiraterone work?
Abiraterone blocks an enzyme called CYP17, which your body needs to produce androgens such as testosterone. This reduces hormone production in your testes, adrenal glands and prostate tumour tissue.

3. Why do you need ADT alongside abiraterone?
ADT mainly reduces testosterone produced by your testes, while abiraterone blocks androgen production from other sources. Using both treatments helps lower the hormones that can encourage prostate cancer growth.

4. Why is prednisolone or prednisone given with abiraterone?
The steroid helps reduce the risk and severity of hormonal side effects such as high blood pressure, low potassium and fluid retention. You should take it as prescribed and never stop it suddenly without medical advice.

5. Can abiraterone treat prostate cancer that hasn’t spread?
Yes. If you have selected high-risk localised or locally advanced prostate cancer, your specialist may recommend abiraterone alongside ADT, with radiotherapy where appropriate. Your specialist will assess whether this combination is suitable for you.

6. Can abiraterone help with metastatic prostate cancer?
Yes. Abiraterone can help slow cancer progression and improve survival in certain men whose prostate cancer has spread. It may be used in hormone-sensitive or castration-resistant disease, depending on previous treatments.

7. What are the common side effects of abiraterone?
Possible side effects include high blood pressure, low potassium, fluid retention, swollen ankles and tiredness. It can also affect your liver, so regular blood tests are important.

8. Why do you need regular blood tests while taking abiraterone?
Your specialist monitors your liver function, potassium levels and blood pressure to identify possible side effects early. Liver tests are usually more frequent during the first three months of treatment.

9. How long can you take abiraterone?
You may take abiraterone for months or years, depending on how well it controls your cancer and whether you experience side effects. If your cancer progresses or treatment becomes unsuitable, your specialist may discuss other options.

10. Is abiraterone safe if you have heart problems?
You may still be able to take abiraterone, but your specialist will assess your heart health carefully. Because it can cause high blood pressure, low potassium and fluid retention, you may need closer monitoring.

Final Thoughts: Is Abiraterone the Right Treatment for Your Prostate Cancer?

Abiraterone can help control certain types of advanced prostate cancer and selected high-risk non-metastatic disease by reducing the androgens that encourage cancer cells to grow. You’ll usually take it alongside ADT and prednisolone or prednisone, with regular checks of your blood pressure, potassium and liver function to monitor for side effects. Whether it’s suitable for you depends on your cancer stage, previous treatments and overall health. Your specialist can explain the potential benefits, possible risks and other treatment options before you decide on your next steps.

If you are considering prostate cancer treatment in London and would like specialist advice, you can contact our team at Prostate Clinic London to discuss your treatment options and arrange a consultation tailored to your individual needs.

References:

  1. Attard, G. et al. (2022) ‘Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol’, The Lancet. Available at: https://pubmed.ncbi.nlm.nih.gov/34953525/
  2. Fizazi, K. et al. (2019) ‘Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial’, The Lancet Oncology. Available at: https://pubmed.ncbi.nlm.nih.gov/30987939/
  3. Fizazi, K. et al. (2012) ‘Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study’, The Lancet Oncology, 13(10), pp. 983–992. Available at: https://pubmed.ncbi.nlm.nih.gov/22995653/
  4. NHS England (2026) Abiraterone acetate and prednisolone for high-risk, hormone sensitive, non-metastatic prostate cancer (adults). Available at: https://www.england.nhs.uk/publication/abiraterone-acetate-and-prednisolone-for-high-risk-hormone-sensitive-non-metastatic-prostate-cancer-adults/
  5. National Institute for Health and Care Excellence (2025) Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. Technology appraisal guidance TA1110. Available at: https://www.nice.org.uk/guidance/TA1110
  6. Electronic Medicines Compendium (2026) Abiraterone 250 mg film-coated tablets: Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/14566/smpc
  7. Ryan, C.J. et al. (2015) ‘Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study’, The Lancet Oncology, 16(2), pp. 152–160. Available at: https://pubmed.ncbi.nlm.nih.gov/25601341/